A germline JAK2 SNP is associated with predisposition to the development of JAK2V617F-positive myeloproliferative neoplasms
Open Access
- 15 March 2009
- journal article
- research article
- Published by Springer Science and Business Media LLC in Nature Genetics
- Vol. 41 (4), 455-459
- https://doi.org/10.1038/ng.342
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24 577 first-degree relatives of 11 039 patients with myeloproliferative neoplasms in SwedenBlood, 2008
- Comprehensive genomic characterization defines human glioblastoma genes and core pathwaysNature, 2008
- The ‘Common Disease-Common Variant’ Hypothesis and Familial RisksPLOS ONE, 2008
- PLINK: A Tool Set for Whole-Genome Association and Population-Based Linkage AnalysesAmerican Journal of Human Genetics, 2007
- Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controlsNature, 2007
- JAK2Exon 12 Mutations in Polycythemia Vera and Idiopathic ErythrocytosisThe New England Journal of Medicine, 2007
- JAK2T875N is a novel activating mutation that results in myeloproliferative disease with features of megakaryoblastic leukemia in a murine bone marrow transplantation modelBlood, 2006
- Principal components analysis corrects for stratification in genome-wide association studiesNature Genetics, 2006
- The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiationProceedings of the National Academy of Sciences of the United States of America, 2006
- A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia veraNature, 2005